Synergy Pharmaceuticals to Present at 2013 Credit Suisse Healthcare
Credit Suisse Healthcare Conference 2013
NEW YORK -- November 8, 2013
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that Chief
Executive Officer, Gary S. Jacob, Ph.D., will present a corporate update at
the Credit Suisse Healthcare Conference in Scottsdale, Arizona on Thursday,
November 14, 2013 at 9:30 a.m. MST.
A live webcast of Synergy’s presentation will be accessible through the
Investor Relations section of the company’s website at www.synergypharma.com.
A replay of the webcast will be available on Synergy’s website for 60 days.
About Synergy Pharmaceuticals Inc.
Synergy Pharmaceuticals is a biopharmaceutical company focused on the
development of new drugs to treat patients with gastrointestinal (GI) diseases
and disorders. Synergy's lead proprietary drug candidate, plecanatide, is a
synthetic analog of the natural human GI hormone, uroguanylin, and functions
by activating the guanylate cyclase-C (GC-C) receptor on epithelial cells of
the GI tract. In early 2013, Synergy announced positive results from a large
multicenter trial of plecanatide in patients with chronic idiopathic
constipation (CIC) and completed an end-of-phase 2 meeting with the U.S. Food
and Drug Administration (FDA) in July covering the registration program for
plecanatide to treat CIC. The company plans to initiate the phase 3
registration trial for plecanatide in CIC this quarter. Synergy is also
developing plecanatide for the treatment of irritable bowel syndrome with
constipation (IBS-C) and plans to announce topline data results from its
ongoing phase 2b study with IBS-C patients in 1Q2014. Synergy’s second GC-C
agonist, SP-333, is in clinical development to treat opioid-induced
constipation (OIC) and ulcerative colitis (UC). SP-333 has successfully
completed phase I single and multiple ascending dose studies in healthy
volunteers and is currently in a phase 2 clinical trial for OIC. More
information is available at www.synergypharma.com.
Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward- looking words such as
"anticipate," "planned," "believe," "forecast," "estimated," "expected," and
"intend," among others. These forward-looking statements are based on
Synergy's current expectations and actual results could differ materially.
There are a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements. These
factors include, but are not limited to, substantial competition; our ability
to continue as a going concern; our need for additional financing;
uncertainties of patent protection and litigation; uncertainties of government
or third party payer reimbursement; limited sales and marketing efforts and
dependence upon third parties; and risks related to failure to obtain FDA
clearances or approvals and noncompliance with FDA regulations. As with any
pharmaceutical under development, there are significant risks in the
development, regulatory approval and commercialization of new products. There
are no guarantees that future clinical trials discussed in this press release
will be completed or successful or that any product will receive regulatory
approval for any indication or prove to be commercially successful. Investors
should read the risk factors set forth in Synergy's Form 10-K for the year
ended December 31, 2012 and other periodic reports filed with the Securities
and Exchange Commission. While the list of factors presented here is
considered representative, no such list should be considered to be a complete
statement of all potential risks and uncertainties. Unlisted factors may
present significant additional obstacles to the realization of forward-looking
statements. Forward-looking statements included herein are made as of the date
hereof, and Synergy does not undertake any obligation to update publicly such
statements to reflect subsequent events or circumstances.
Synergy Pharmaceuticals Inc.
Gem Gokmen, 212-584-7610
Bernard Denoyer, 212-297-0020
Press spacebar to pause and continue. Press esc to stop.